PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Syndax Pharmaceuticals, Inc. (SNDX)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS87164F1057
CUSIP87164F105
SectorHealthcare
IndustryBiotechnology
IPO DateMar 3, 2016

Highlights

Market Cap$1.38B
EPS (TTM)-$3.64
Total Revenue (TTM)$16.54M
Gross Profit (TTM)-$28.07M
EBITDA (TTM)-$315.71M
Year Range$14.50 - $25.34
Target Price$36.08
Short %12.60%
Short Ratio14.84

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons: SNDX vs. VKTX, SNDX vs. WMT

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Syndax Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-30.00%-20.00%-10.00%0.00%10.00%JuneJulyAugustSeptemberOctoberNovember
-25.16%
14.05%
SNDX (Syndax Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Returns By Period

Syndax Pharmaceuticals, Inc. had a return of -24.99% year-to-date (YTD) and 16.96% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date-24.99%25.45%
1 month-15.26%2.91%
6 months-25.16%14.05%
1 year16.96%35.64%
5 years (annualized)19.22%14.13%
10 years (annualized)N/A11.39%

Monthly Returns

The table below presents the monthly returns of SNDX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-5.18%14.40%1.54%-11.22%-8.80%6.54%10.57%-9.47%-6.33%-2.03%-24.99%
202312.77%-11.67%-16.69%-2.70%-2.82%4.81%1.86%-13.18%-21.56%-3.03%18.22%29.83%-15.09%
2022-25.35%-4.59%11.48%-3.51%-1.61%16.61%5.87%15.91%1.78%-4.45%4.36%6.22%16.26%
2021-9.89%21.81%-8.40%-28.71%15.24%-6.53%-15.08%19.96%9.26%1.78%-17.89%37.07%-1.57%
20206.83%0.32%16.58%64.08%-10.00%-8.52%-4.79%15.59%-9.50%17.95%33.08%-4.01%153.30%
201925.84%10.18%-14.91%36.19%2.10%27.53%3.11%-12.40%-11.18%-10.04%8.48%20.44%97.30%
201824.43%-17.06%57.41%-26.63%-16.38%-19.59%-3.99%15.13%4.12%-40.47%6.03%-12.75%-49.20%
20176.00%49.74%20.56%-30.83%27.92%15.07%-13.31%-4.21%0.86%-4.44%-21.65%0.00%22.18%
201610.91%2.78%0.37%-28.31%26.09%14.17%6.91%-22.10%-18.04%-25.93%-40.30%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of SNDX is 51, suggesting that the investment has average results relative to other stocks in terms of risk-adjusted performance. This ranking is determined by the cumulative values of the indicators listed below.


The Risk-Adjusted Performance Rank of SNDX is 5151
Combined Rank
The Sharpe Ratio Rank of SNDX is 5252Sharpe Ratio Rank
The Sortino Ratio Rank of SNDX is 4646Sortino Ratio Rank
The Omega Ratio Rank of SNDX is 4848Omega Ratio Rank
The Calmar Ratio Rank of SNDX is 5656Calmar Ratio Rank
The Martin Ratio Rank of SNDX is 5353Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Syndax Pharmaceuticals, Inc. (SNDX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


SNDX
Sharpe ratio
The chart of Sharpe ratio for SNDX, currently valued at 0.38, compared to the broader market-4.00-2.000.002.004.000.38
Sortino ratio
The chart of Sortino ratio for SNDX, currently valued at 0.82, compared to the broader market-4.00-2.000.002.004.006.000.82
Omega ratio
The chart of Omega ratio for SNDX, currently valued at 1.12, compared to the broader market0.501.001.502.001.12
Calmar ratio
The chart of Calmar ratio for SNDX, currently valued at 0.38, compared to the broader market0.002.004.006.000.38
Martin ratio
The chart of Martin ratio for SNDX, currently valued at 1.33, compared to the broader market0.0010.0020.0030.001.33
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 2.90, compared to the broader market-4.00-2.000.002.004.002.90
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 3.87, compared to the broader market-4.00-2.000.002.004.006.003.87
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.54, compared to the broader market0.501.001.502.001.54
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 4.19, compared to the broader market0.002.004.006.004.19
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 18.72, compared to the broader market0.0010.0020.0030.0018.72

Sharpe Ratio

The current Syndax Pharmaceuticals, Inc. Sharpe ratio is 0.38. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Syndax Pharmaceuticals, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio0.001.002.003.00JuneJulyAugustSeptemberOctoberNovember
0.38
2.90
SNDX (Syndax Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Syndax Pharmaceuticals, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-40.00%-30.00%-20.00%-10.00%0.00%JuneJulyAugustSeptemberOctoberNovember
-44.06%
-0.29%
SNDX (Syndax Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Syndax Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Syndax Pharmaceuticals, Inc. was 78.98%, occurring on Dec 24, 2018. Recovery took 337 trading sessions.

The current Syndax Pharmaceuticals, Inc. drawdown is 44.06%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-78.98%Aug 24, 2016588Dec 24, 2018337Apr 28, 2020925
-60.7%Feb 2, 2023182Oct 23, 2023
-49.24%Dec 22, 202081Apr 20, 2021437Jan 12, 2023518
-45.42%Apr 7, 201657Jun 27, 201640Aug 23, 201697
-36.18%May 18, 202048Jul 24, 202073Nov 5, 2020121

Volatility

Volatility Chart

The current Syndax Pharmaceuticals, Inc. volatility is 31.88%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%25.00%30.00%35.00%JuneJulyAugustSeptemberOctoberNovember
31.88%
3.86%
SNDX (Syndax Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Syndax Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Syndax Pharmaceuticals, Inc..


Loading data...

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items